Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang; Gang Zeng; Hongxing Pan; Changgui Li; Yaling Hu; Kai Chu; Weixiao Han; Zhen Chen; Rong Tang; Weidong Yin; Xin Chen; Yuansheng Hu; Xiaoyong Liu; Congbing Jiang; Jingxin Li; Minnan Yang; Yan Song; Xiangxi Wang; Qiang Gao; Fengcai Zhu

doi:10.1016/s1473-3099(20)30843-4

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang(Zhejiang Center for Disease Control and Prevention), Gang Zeng(Sinovac Biotech), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Changgui Li(National Institutes for Food and Drug Control), Yaling Hu(Sinovac Biotech), Kai Chu(Jiangsu Provincial Center for Disease Control and Prevention), Weixiao Han(Sinovac Biotech), Zhen Chen(National Institutes for Food and Drug Control), Rong Tang(Jiangsu Provincial Center for Disease Control and Prevention), Weidong Yin(Sinovac Biotech), Xin Chen(Suizhou Central Hospital), Yuansheng Hu(Sinovac Biotech), Xiaoyong Liu(Suizhou Central Hospital), Congbing Jiang(Suizhou Central Hospital), Jingxin Li(Jiangsu Provincial Center for Disease Control and Prevention), Minnan Yang(Chinese Academy of Sciences), Yan Song(Suizhou Central Hospital), Xiangxi Wang(Chinese Academy of Sciences), Qiang Gao, Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention)

The Lancet Infectious Diseases

November 18, 2020

10.1016/s1473-3099(20)30843-4

Cited by 1,507Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis